Haematologica (Mar 2008)

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

  • Jean El-Cheikh,
  • Mauricette Michallet,
  • Arnon Nagler,
  • Hugues de Lavallade,
  • Franck E. Nicolini,
  • Avichai Shimoni,
  • Catherine Faucher,
  • Mohamad Sobh,
  • Daniela Revesz,
  • Izhar Hardan,
  • Sabine Fürst,
  • Didier Blaise,
  • Mohamad Mohty

DOI
https://doi.org/10.3324/haematol.12184
Journal volume & issue
Vol. 93, no. 3

Abstract

Read online

We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1–2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59–87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.